Together with growing evidence from preclinical and clinical studies [24–27], our observations highlight potential of targeting STAT3 and/or PD-L1 to improve CMT efficacy in HNSCC patients possibly by neutralizing this checkpoint molecule on immunosuppressive myeloid cells as well as cancer cells. This evidence concerns the gene STAT3 and cancer.